1173289-66-1

Basic information

• Product Name: (S)-2-(3-benzoylphenyl)-N-(4-hydroxyphenethyl)-N-isopropylpropanamide
• Synonyms: (S)-2-(3-benzoylphenyl)-N-(4-hydroxyphenethyl)-N-isopropylpropanamide;(S)-2-(3-benzoylphenyl)-N-(4-hydroxyphenethyl)-N-isopropylpropan
• CAS NO: 1173289-66-1
• Molecular Formula: C₂₇H₂₉NO₃
• Molecular Weight: 415.52406
• Mol File: 1173289-66-1.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 612.0±55.0 °C(Predicted)
• Appearance: /
• Density: 1.142±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 10.00±0.15(Predicted)
• CAS DataBase Reference: (S)-2-(3-benzoylphenyl)-N-(4-hydroxyphenethyl)-N-isopropylpropanamide(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-(3-benzoylphenyl)-N-(4-hydroxyphenethyl)-N-isopropylpropanamide(1173289-66-1)
• EPA Substance Registry System: (S)-2-(3-benzoylphenyl)-N-(4-hydroxyphenethyl)-N-isopropylpropanamide(1173289-66-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 1173289-66-1(Hazardous Substances Data)

Usage

General Description

The chemical compound "(S)-2-(3-benzoylphenyl)-N-(4-hydroxyphenethyl)-N-isopropylpropanamide" is an inhibitor of the enzyme fatty acid amide hydrolase (FAAH) and has potential pharmaceutical applications. It is a synthetic compound that belongs to the class of N-acyl amino acids and is known for its role in modulating the endocannabinoid system. (S)-2-(3-benzoylphenyl)-N-(4-hydroxyphenethyl)-N-isopropylpropanamide has shown promise in preclinical studies for its potential therapeutic effects, including pain relief, anti-inflammatory properties, and potential use in the treatment of neurological disorders. It is a complex molecule that has garnered attention for its potential pharmacological properties and is being researched for its potential use in medical applications.

Upstream product

• 22161-81-5 S-ketoprofen 
• 156349-08-5 4-(2-(1-propylamino)ethyl)phenol 

Relevant articles and documents

Structure-activity relationships and cancer-cell selective toxicity of novel inhibitors of glioma-associated oncogene homologue 1 (Gli1) mediated transcription

We report novel inhibitors of Gli1-mediated transcription as potential anticancer agents. Focused chemical libraries were designed and assessed for inhibition of functional cell-based Gli1-mediated transcription and selective toxicity toward cancer cells. The SAR was revealed, and the selectivity of the lead compounds' inhibition of Gli1-mediated transcription over that of Gli2 was determined. Compound 63 (NMDA298-1), which inhibited Gli1-mediated transcription in C3H10T1/2 cells with an IC50 of 6.9 μM, showed 3-fold selectivity for inhibiting transcription mediated by Gli1 over that by Gli2. Cell-viability assays were performed to evaluate the chemical library in a normal cell line and a panel of cancer cell lines with or without up-regulated expression of the Gli1 gene. These compounds decreased the viability of several cancer cell lines but were less active in the noncancerous BJ-hTERT cells. 2009 American Chemical Society.